We identified in breast cancer cases two germline alterations, R62H and R71W, in presenilin-2 (PS-2), a gene involved in familial Alzheimer's disease (FAD). The role of these alleles in FAD is unclear, but neither allele affected Ab(42)/Ab(40) ratio. However, both R62H and R71W alterations compromised PS-2 function in Notch signaling in Caenorhabditis elegans and cell growth inhibition in mouse embryonic fibroblasts, and these effects were dependent on gene dosage. We found that both alterations enhanced the degradation of the PS-2 full-length protein, indicating that they may have a loss-of function effect. The effect of the R71W alteration was noticeably stronger, and we observed an almost threefold higher frequency of this allele in breast cancer cases versus controls, but this difference did not reach statistical significance. Nonetheless, these results collectively suggest that the novel PS-2 alleles described here, especially R71W, affect PS-2 function and may potentially confer a moderate risk of susceptibility to breast cancer.
Introduction
Presenilins were originally identified as part of the molecular etiology of familial Alzheimer's disease (FAD) (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995) , with mutations accounting for the majority of early-onset FAD cases. The two human presenilin genes, PS-1 and PS-2, encode polytopic proteins that share greater than 60% identity at the amino-acid level, and both have been localized to multiple membranous compartments of cells (De Strooper et al., 1997; Li et al., 1997) . In addition, full-length PS-1 (PS-1 FL ) and PS-2 (PS-2 FL ) proteins are similarly processed post-translationally into respective amino (NTF) and carboxyl (CTF) fragments that remain associated to form bioactive complexes Podlisny et al., 1997) . In spite of these similarities, PS-1 and PS-2 do not appear to share an equal contribution to the etiology of FAD. Whereas numerous high-penetrance mutations in PS-1 have been identified in FAD families, mutations in PS-2 are rare (Hutton and Hardy, 1997) and are associated with a variable penetrance and a wider range in age of disease onset (Bird et al., 1996; Sherrington et al., 1996) . Nonetheless, FAD mutations in both genes do appear to share a common pathogenic mechanism associated with aberrant processing of the b-amyloid precursor protein (b-APP), increasing the production and secretion of the amyloidogenic Ab(42) peptide that constitutes a major component of the amyloid plagues commonly found in the brains of Alzheimer's disease patients (Scheuner et al., 1996; Citron et al., 1997) .
Genetic studies in mouse (Donoviel et al., 1999; Herreman et al., 1999) , Drosophila melanogaster (Struhl and Greenwald, 1999; Ye et al., 1999) and Caenorhabditis elegans (Levitan and Greenwald, 1995) indicated that PS-1 and PS-2 proteins normally function as important regulators in Notch signaling, a pathway known to be deregulated in neoplasia (Joutel and Tournier-Lasserve, 1998) . At the cellular level, PS-1 and PS-2 function to negatively control cell proliferation (Janicki and Monteiro, 1999; Jeong et al., 2000; Soriano et al., 2001) , and PS-2 in particular has also been associated with a proapoptotic activity (Deng et al., 1996; Wolozin et al., 1996) . Loss of PS-1 in murine epidermal tissues resulted in skin tumorigenesis (Xia et al., 2001) , suggesting that presenilins may possess tumor-suppressing activities. A number of studies have shown that PS-1 may have a role in downregulating the level of b-catenin protein (Xia et al., 2001; Kang et al., 2002) , thus pointing to a potential mechanism for PS-1-mediated cell cycle control. Evidence suggests that PS-2 is also capable of regulating the level of b-catenin (Janicki et al., 2000) , as well as being involved in a p53-dependent mechanism of cell growth regulation. PS-2 has been found to have a strong synergistic effect on p53-mediated transcriptional activation of downstream genes (Alves da Costa et al., 2002) , many of which are known to be important in cell cycle regulation and apoptosis. Both p53 and b-catenin, as well as a number of genes in their respective pathways, are targets of mutations or deregulation during tumorigenesis. Thus, it is possible that alterations affecting the presenilins might contribute to the development of cancer.
PS-2 maps to the chromosomal region 1q42-43 (Takano et al., 1997) , where loss of heterozygosity has been found to occur in breast cancer (Chen et al., 1989) . In addition, we detected deletion at the PS-2 locus and reduced levels of PS-2 expression in breast tumors (MD To and IL Andrulis, unpublished results). To further investigate the potential role of PS-2 in human cancer, we analysed primary tumor specimens and blood DNA from breast cancer cases for the presence of sequence alterations. In this work, we describe two germline alterations in PS-2 and functional studies to characterize the effects of these changes on PS-2 function. We also determined the frequency of these PS-2 alleles in DNA from breast cancer cases and controls.
Results

Detection of PS-2 alterations
To explore the possibility that PS-2 has a role in cancer, we undertook a mutational analysis of PS-2 in primary tumor specimens. We initially focused on the coding region of the gene that encodes the hydrophilic aminoterminal domain because this region has not been found to harbor mutations in FAD. By using a combination of single-strand conformation polymorphism (SSCP) analysis (not shown) and direct DNA sequencing (Figure 1a) , we identified two sequence changes, both resulting in amino-acid substitutions (Figure 1b) . The CGC>CAC alteration occurs at codon 62, resulting in a substitution of histidine for arginine (R62H). The CGG>TGG alteration occurs at codon 71, leading to an arginine to tryptophan (R71W) missense change. The R62 and R71 residues are conserved in human PS-1 and PS-2 proteins, and both alterations are distinct from mutations in PS-2 involved in FAD (Levy-Lahad et al., 1995; Sherrington et al., 1995) . Both R62H and R71W alterations were initially identified in primary tumor specimens, and subsequently in blood DNA from unrelated individuals with breast cancer, indicating that they are germline variants.
R62H and R71W alleles do not affect Ab(42)/Ab(40) ratio FAD-linked mutations in both PS-1 and PS-2 are associated with an increase in production and secretion of the Ab(42) peptide (Scheuner et al., 1996; Citron et al., 1997) , a major component of the amyloid plaques deposited in the brains of Alzheimer's disease patients. To assess the effect of the R62H and R71W alterations in PS-2 on b-APP processing, we co-transfected HEK-293 cells with b-APP and PS-2 cDNAs, and measured the levels of secreted Ab peptides from independently transfected cultures. Western analysis (Figure 2a ) demonstrated an accumulation of PS-2 FL protein in cells transfected with exogenous PS-2 but not in cells transfected with vector control, as expected. As previously described (Thinakaran et al., 1997) , the levels of PS-2 NTF and PS-2 CTF proteolytic products remain unchanged, despite accumulating PS-2 FL because the factors required for the endoproteolytic event are present in limiting quantities. However, it is expected that PS-2 NTF and PS-2 CTF , which constitute a bioactive complex, detected in these cells are derived predominantly from the more abundant exogenous PS-2 FL in what has been described as a 'replacement effect' (Thinakaran et al., 1997) . In agreement with previous studies (Scheuner et al., 1996; Citron et al., 1997) , expression of FAD-linked mutations in PS-2 resulted in a clear increase in the level of secreted Ab(42) peptide, as reflected in a higher Ab(42)/ Ab(40) ratio (Figure 2b ). In contrast, the ratios of Ab(42)/Ab(40) secreted from cells expressing either PS-2(R62H) or PS-2(R71W) remained comparable to that of cells expressing PS-2(WT). These results indicate that, unlike FAD mutations, the R62H and R71W alleles of PS-2 described here do not alter Ab(42)/Ab(40) ratio. Novel PS-2 variants in human breast cancer MD To et al R62H and R71W alterations compromise PS-2 function in Notch signaling Loss-of-function mutations in sel-12, a C. elegans ortholog of presenilins, result in an egg laying (Egl) defect because of improper Notch signaling (Levitan and Greenwald, 1995) . That both PS-1 and PS-2 can compensate for the sel-12 deficiency provided evidence for a role of the human presenilin genes in Notch signaling (Levitan et al., 1996; Baumeister et al., 1997) , a conclusion consistent with the dysregulated Notch signaling in mouse embryos carrying null mutations in both PS-1 and PS-2 (Donoviel et al., 1999; Herreman et al., 1999) . FAD variants of PS-1 and PS-2 rescue the Egl phenotype at a lower efficiency than the WT genes (Levitan et al., 1996; Baumeister et al., 1997) ; thus, the C. elegans assay can be used to assess the biological function of different alleles of PS-2. We established multiple lines of transgenic C. elegans animals expressing human PS-2(WT), PS-2(R62H) or PS-2(R71W) in order to assess the effect of the alterations on PS-2 function. At least 40 hermaphrodite animals from each transgenic line were scored for their ability to lay eggs. The efficiencies of Egl rescue were dramatically lower in animals expressing PS-2(R62H) or PS-2(R71W) in comparison to those expressing PS-2(WT) (Figure 3a ), indicating that these alterations compromised the protein function of PS-2 in Notch signaling. The effects of these alterations were dose dependent: when the amount of transgene DNA microinjected into parental hermaphrodite germlines was increased 10-fold, the ability of PS-2(R62H) and PS-2(R71W) to rescue the Egl defect approached that of PS-2(WT) (Figure 3b ).
Formation of PS-2 heterodimeric complexes is not affected by the R62H and R71W alterations
Critical to PS-2 function are the endoproteolysis of PS-2 FL protein and the assembly of the resultant fragments into heterodimeric complexes (Podlisny et al., 1997; Yu et al., 1998; Saura et al., 1999) . PS-2 FL is not commonly observed under physiological conditions because it is rapidly degraded in vivo (Podlisny et al., 1997) . However, uncleaved PS-2 FL protein is not devoid of activity, and is capable of rescuing the Egl phenotype when accumulated to high levels (Jacobsen et al., 1999) . Under such scenario, the level of rescue would be dependent on gene dosage, which we observed with the R62H and R71W alleles. Thus, it is possible that the alterations affected PS-2 FL endoproteolysis or subsequent heterodimeric complex formation.
To explore these possibilities, we transiently expressed the PS-2 alleles in NIH-3T3 cells, which we found to have no endogenous PS-2 protein, and cell lysates were immunoprecipitated with an antibody specific to PS-2 NTF . As shown in Figure 4a Effects of the R62H and R71W alterations on PS-2 ability to rescue the Egl defect in C. elegans. Each vertical bar represents an independent transgenic line, from which more than 40 different animals were scored for their egg-laying phenotype. The proportion of animals capable of laying eggs (Egl þ ) is a measurement of the efficiency of the human PS-2 allele to rescue the sel-12 deficiency. Transgenic lines were generated by injecting parental sel-12-deficient hermaphrodites with constructs containing the indicated human PS-2 allele at concentrations of (a) 5 mg/ml and (b) 50 mg/ml. There was no rescue with the empty PIN4 vector (see Materials and methods). (42) and Ab(40) peptides secreted from HEK293 cells into the conditioned media were quantified by a sensitive ELISA assay . The Volga German (VG; N141I) and Italian (Ita; M239V) FAD-linked alleles of PS-2 were used as positive controls.
alleles. In addition, PS-2 CTF protein fragments were also observed in these cells (Figure 4a, right) , indicating that the alterations do not interfere with the endoproteolysis of PS-2 FL . PS-2 CTF was also clearly present in the PS-2 NTF immunoprecipitates (Figure 4a, right) , demonstrating that the ability of PS-2 NTF and PS-2 CTF to form heterodimer complexes was not compromised by the R62H and R71W alterations.
The R62H and R71W forms of PS-2 exhibit reduced protein stability The dose-dependent effect of the R62H and R71W alleles in the Egl assay suggests that these alleles may affect the stability of PS-2 protein. To test this possibility, we assessed the stability of PS-2(WT), PS-2(R62H) and PS-2(R71W) proteins in retrovirally infected NIH-3T3 treated with cycloheximide by immunoblotting (Figure 4b ). PS-2 NTF was stable, a finding consistent with published studies (Podlisny et al., 1997) , with no apparent decrease in levels even after 2.75 h of chase in cycloheximide, irrespective of the sequence variants. In contrast, PS-2 FL was rapidly degraded as previously described (Podlisny et al., 1997) , and the two alterations further enhanced this rate of degradation. Whereas the half-life (t 1/2 ) of PS-2 FL (WT) was 4572 min, the t 1/2 of PS-2 FL (R62H) and PS-2 FL (R71W) were 2976 and 1371 min, respectively. Similar results were obtained using 35 S-methionine pulse-chase (data not shown).
To examine the effect of decreased PS-2 FL stability on the level of the proteolytic fragments, we infected PS-2(À/À) mouse embryonic fibroblasts (MEFs) with replication-incompetent retrovirus carrying different PS-2 alleles. We carefully controlled the multiplicity of infection (MOI) to ensure equal gene dosage input in each case. As shown in Figure 4c , the levels of PS-2 NTF in cells infected with PS-2(R62H) and PS-2(R71W) were lower than the corresponding levels of PS-2 NTF in cells infected with PS-2(WT) at the same MOI. PS-2 NTF was least abundant in cells infected with PS-2(R71W), consistent with the short t 1/2 of PS-2 FL (R71W). Together, these results indicated that the R62H and R71W forms of PS-2 FL protein are more susceptible to degradation, resulting in a lower steady-state level of the physiologically active proteolytic PS-2 protein fragments. PS-2 NTF protein fragment was detected using the DT2 antibody.
Novel PS-2 variants in human breast cancer MD To et al R62H and R71W alterations compromise the cell growth inhibitory function of PS-2 To assess the effect of the R62H and R71W alleles of PS-2 on cell growth, we performed growth assays using the PS-2(À/À) MEFs infected with retrovirus carrying various PS-2 alleles at different MOI, as described above. At an MOI of 250 (Figure 5a ), cells infected with the PS-2(WT) allele grew at a slower rate than control cells. This observation is in agreement with previous findings demonstrating the ability of PS-2 to impede cellular growth (Janicki and Monteiro, 1999; Jeong et al., 2000) . In contrast, cells infected with either PS-2(R62H) or PS-2(R71W) at an MOI of 250 continued to grow at rates similar to those of control cells, indicating that the same input amount of transgene does not impede cell growth. At lower MOI, cells expressing different forms of PS-2 grew at rates similar to those of control cells (data not shown).
We further assessed the growth rates of PS-2(À/À) MEFs infected with a higher MOI of 400. At this MOI, both R62H and R71W alleles of PS-2 were as capable as the WT allele in inhibiting cell growth (Figure 5b ).
It appears that the inefficiency of PS-2(R62H) and PS-2(R71W) in impeding cell growth can be compensated for by increasing their levels of expression, a finding reminiscent of the results of the Egl rescue assay.
Prevalence of the PS-2 alleles in breast cancer cases and controls We had initially identified the R62H and R71W alleles of PS-2 in DNA from primary tumor specimens. To determine whether these variants were somatic or germline changes, we studied breast cancer cases and controls. In total, we determined the frequency of the alleles in 844 breast cancer cases and 587 non-cancer controls. The frequency of the R62H allele in cases (0.95%) and controls (0.85%) was similar, suggesting that it may be a polymorphism. In contrast, we observed the R71W variant in four of 844 (0.47%) cases and only one of 587 (0.17%) controls. Although the R71W allele occurred almost threefold more frequently in the breast cancer cases, the difference in frequency in cases versus controls was not statistically significant.
Discussion
In this paper, we have identified two germline alterations in the PS-2 gene and characterized their effects on PS-2 function. Both R62H and R71W alterations are distinct from mutations that have been unequivocally demonstrated to be involved in FAD. There has been one case of sporadic AD with the R62H allele (Cruts et al., 1998) , but the relationship of this allele to AD is not clear. To our knowledge, the R71W allele has yet to be reported. In contrast to FAD-linked mutations, we did not detect an alteration in the Ab(42)/Ab(40) ratio with the R62H or R71W alleles. A lack of effect on the Ab(42)/Ab(40) ratio by the R62H variant has previously been described (Walker et al., 2005) . We cannot rule out the possibility of these PS-2 alleles affecting other aspects of b-APP processing, as previously reported for a number of PS-2 variants (Walker et al., 2005) . However, as aberrant accumulation of Ab(42) has emerged as a hallmark of AD pathobiology, a lack of effect on Ab(42)/Ab(40) argues against the R62H and R71W alleles as having a role in AD etiology.
Functional effects of the R62H and R71W PS-2 germline alterations
The lower efficiencies of the R62H and R71W alleles of human PS-2 to rescue the Egl phenotype in comparison to the WT counterpart provided strong in vivo evidence in support of a loss-of-function effect caused by these alterations. In contrast to FAD-linked missense mutations in the presenilins, which also cause a reduction in the efficiency of Egl rescue (Levitan et al., 1996) , we observed that an increase in gene copy number of the R62H and R71W alleles could compensate for the reduced efficiency of these transgenes in rescuing the Egl phenotype. The dose-dependent properties of these alleles suggest that the R62H and R71W alterations are hypomorphic, not null, mutations in the PS-2 gene.
Consistent with this conclusion, the data presented here suggest that the R62H and R71W alterations affect PS-2 protein stability. PS-2 FL protein is rapidly degraded, and proteins harboring the R62H or R71W alterations are more susceptible to degradation. It is clear that the R71W alteration has a more drastic effect on PS-2 FL degradation, suggesting that there is potential for a stronger biological effect than the R62H alteration. However, although both alterations enhanced PS-2 FL degradation, they did not appear to have any effect on the stability of PS-2 NTF . A decrease in the stability of PS-2 FL would nonetheless result in lower steady-state levels of the endoproteolytic products, as confirmed in PS-2(À/À) MEFs retrovirally infected with PS-2 transgenes.
It is not clear how the two alterations can render PS-2 FL more susceptible to degradation, while not have any discernible effect on the stability of PS-2 NTF . The basis for the differences in stability between holoprotein and endoproteolytic products of WT PS-2 also remains unclear. Evidence suggests that heterodimeric complex formation between PS-2 NTF and PS-2 CTF is not only essential for PS-2 function, but also contributes to the stability of these endoproteolytic fragments (Steiner et al., 1998) . In this respect, both the R62H and R71W forms of PS-2 were able to participate fully in heterodimeric complex formation. On the other hand, it is possible that the alterations affected the ingress of PS-2 FL into a high-molecular-weight protein (HMW) complex, thereby rendering R62H and R71W forms of PS-2 FL proteins more susceptible to degradation by delaying their maturation (Yu et al., 2000) . It is significant that mutant PS-2 FL proteins that fail to enter the HMW complex also interfere with the maturation of WT PS-2 FL , thus exerting a dominant-negative effect (Yu et al., 2000) .
PS-2 negatively regulates cell growth (Janicki and Monteiro, 1999; Jeong et al., 2000) , suggesting that the protein may be associated with tumor-suppressing activity. Consistent with this possibility, we found that expression of PS-2(WT) inhibited the growth of PS-2(À/À) MEFs at MOI of 250 and 400. A lack of growth inhibition at lower MOI suggested that the effect of PS-2 is dose dependent. In contrast to PS-2(WT), both PS-2(R62H) and PS-2(R71W) did not affect the rate of cell growth at an MOI of 250, as cells expressing these PS-2 alleles continued to grow at a rate similar to that of control cells. However, the difference in growth between cells expressing these alleles versus WT PS-2 is moderate. From a functional perspective, it is possible that phenotypic manifestations of loss-of-function PS-2 alleles would be modulated by the presence of the PS-1 gene in the cell. On the other hand, that differences in growth between cells expressing the R62H and R71W alleles and WT PS-2 can be detected despite the presence of PS-1 is supported by previous studies describing PS-2 and PS-1 as having overlapping but not completely redundant functions (Donoviel et al., 1999; Herreman et al., 1999) .
Our data further demonstrated that the inhibitory effect of PS-2 is not completely negated by the R62H and R71W alterations. In a manner that parallels the dose-dependent effect previously observed in C. elegans, both R62H and R71W PS-2 alleles were found to be as capable as WT PS-2 in impeding cell growth when their levels of expression were increased by augmenting MOI. Results from these functional assays support the notion that the effect of the R62H and R71W alterations on PS-2 function is quantitative, rather than qualitative. For this reason, the expression levels of PS-2, as well as PS-1, in a particular tissue may be important factors in modulating the susceptibility of cells in that tissue to the pathogenic effect of these alterations.
Potential role of PS-2 in cancer susceptibility Insight into cancer genetics has been gathered mainly from studies of strong predisposition alleles, such as those of BRCA1/2 and APC, which confer a high degree of susceptibility to breast and colon cancer, respectively. However, germline mutations in these genes account for only a small fraction of the total human cancer burden. It has been proposed that the majority of cancer cases are the result of combinations of a small number of moderately strong genes, and a larger number of weak predisposition genes (Ponder, 2001) . The effects of the R62H and R71W alleles on cell growth argue that they could render cells moderately susceptible to malignant growth and individuals moderately predisposed to cancer development. Although we did not observe a difference in frequency of the R62H allele between breast cancer cases and controls, the frequency of the R71W allele was almost threefold higher in breast cancer cases versus controls. This difference did not, however, reach statistical significance, possibly because of an inadequate sample size. It is possible that the effect of the R71W allele is greater than that conferred by the R62H allele, as the R71W alteration had a noticeably greater effect on PS-2 protein stability. Because the R71W alteration affects aspects of PS-2 functions that may contribute to tumorigenesis, it would be interesting to design larger case-control studies to investigate in more depth a possible role of this PS-2 allele in breast cancer predisposition.
Materials and methods
Breast cancer population
Breast tumors were obtained as part of a prospective study of molecular alterations in axillary node-negative disease (Andrulis et al., 1998) . Following frozen section diagnosis of invasive cancer, tumor specimens were sampled by a pathologist and immediately snap-frozen and stored in liquid nitrogen. Blood DNA from breast cancer patients was obtained from the Ontario site (Knight et al., 2002) of the Breast Cancer Family Registry (www.cfr.epi.uci.edu). The mean age at diagnosis of the breast cancer cases was 49 years. DNA and RNA were extracted by conventional techniques.
Non-cancer population Blood DNA from individuals without a cancer diagnosis was used in the molecular analysis. Of the 587 non-cancer controls used in the study, 100 were obtained from Dr P Ray (Hospital for Sick Children, Toronto), and the remaining 487 were part of a series of population control women collected using randomly selected residential telephone numbers. The mean age at blood draw for the series of population control women was 48 years.
Mutational analysis SSCP analysis was performed as described previously (Gokgoz et al., 2001) . PS-2 primers AZ-4F (5 0 -CGTGCATTACATGG ATAGGC-3 0 ) and AZ-4R (5 0 -GCTTCGCTCCGTATTTGA GG-3 0 ) were used to amplify a 183 bp product directly from genomic DNA. Sequence alterations, which were detected as electrophoretic mobility shifts on SSCP gels, were confirmed by direct DNA sequencing. Sequence alterations were introduced into cloned PS-2 cDNA by sequential PCR mutagenesis.
Analysis of PS-2 protein expression
Cells were lysed with a modified STEN lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 0.1% SDS, 1% Triton X-100), and total soluble proteins were quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts of total cellular proteins were subjected to SDS-PAGE and transferred to Hybond ECL nitrocellulose membrane (Amersham Pharmacia, Uppsala, Sweden). Ponceau S staining was used to confirm equal protein loading. The monoclonal antibody DT-2 or the polyclonal antibodies NT-14 were used to detect PS-2 NTF . PS-2 CTF was detected with the polyclonal antibodies aPS2LOOP. Signals were detected by chemiluminescence as recommended by the manufacturer (Amersham Pharmacia).
Analysis of Ab protein secretion HEK293 cells were co-transfected with pZeo/APP and pcDNA3.1/PS-2 cDNAs using SuperFect (Qiagen Inc., Santa Clarita, CA, USA). Confluent 6 cm dishes were conditioned for 24 h in 2 ml medium containing 10% FBS. ELISA assays for analysis of Ab peptide secretion were as described .
C. elegans rescue assay Human PS-2(WT), PS-2(R62H) and PS-2(R71W) cDNAs were inserted into the pIN4 vector for microinjection and expression in C. elegans. This enabled the expression of human PS-2 to be regulated by the sel-12 promoter. To construct pIN4, the pIN2 vector (a SacI to XhoI sel-12 genomic rescuing fragment in pBSII KS þ where the initial ATG had been replaced with a BamHI site, to which immediately upstream a NotI site was added) was digested with XcmI. The unique XcmI site was subsequently blunted, and ligated with an NheI stop linker (New England Biolabs, Beverly, MA, USA) to introduce a STOP codon at position 162 of sel-12. This vector was called pIN3. The B3 kb SacI/BsrFI fragment from pIN3 was purified and subcloned into pBS þ . A 0.8 kb SpeI/EcorRI fragment of pPD49.26, containing the unc-54 3 0 UTR, was blunted and ligated into the blunted BbsI site of the SacI/BsrI fragment in pBS þ . The orientation of the unc-54 3 0 UTR was verified by restriction digestion. The resulting vector was called pIN4. To construct pIN4/PS-2 constructs, pIN4 was digested with BamHI, and the ends were blunted by fill-in. KpnI/XbaI fragments containing human PS-2 (with STOP codon, but no polyadenylation signal) from pcDNA-3/PS-2 constructs were blunted and ligated into the pIN4 vector. The orientation of each insert was confirmed by SmaI digestion.
PIN4 and derivatives were injected at 5 and 50 mg/ml into recipient strains of genotype sel-12(ar171)unc-1(e538). pRF4, a plasmid containing the cloned dominant rol-6(su1006) gene, was used as a cotransformation marker and coinjected at a concentration of 100 mg/ml. F1 Roller progeny were picked, and F2 Roller progeny were used to establish lines. To assess rescue of sel-12(ar171), at least 40 animals from multiple lines were scored for the ability to lay eggs as previously described (Levitan et al., 1996) .
Co-immunoprecipitation
Subconfluent cultures of NIH-3T3 were lysed with cold 0.25% n-dodecyl-a-d-maltoside (Sigma, St Louis, MO, USA) in PBS as previously described (Saura et al., 1999) . Total protein lysates were incubated with DT-2 and Protein G Plus Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 41C. Immunoprecipitates were suspended in 2 Â SDS-PAGE sample buffer, and heated at 451C before being subjected to SDS-PAGE.
Retrovirus preparation and cell infection PS-2 cDNAs were cloned into the pLNCX2 retroviral vector as suggested by the manufacturer (ClonTech, Palo Alto, CA, USA). pLNCX2/PS-2 constructs were transfected into the retrovirus packaging RetroPack PT67 cells (ClonTech) using Fugene 6 (Roche, Indianapolis, IN, USA), and stable clones were isolated following selection with neomycin. Conditioned media from PT67 clones containing infectious, replicationincompetent retroviral particles were collected and stored in aliquots at À701C.
Infection was performed by incubating proliferating target cells with viral particle-containing media, in the presence of polybrene (8 mg/ml), for at least 12 h. The cells were subsequently incubated in normal non-infectious media for a further 24 h before further analysis. For titer determination, a frozen aliquot of retroviral particle was thawed and prepared in 10-fold serial dilutions for infecting cultures of NIH-3T3 cells. The infected cultures were subjected to neomycin selection, and viral titers were determined from the number of colonies in cultures infected with the highest dilution that contained colonies.
Cell growth assays
MEFs were derived from PS-2(À/À) E14.5 embryos (Donoviel et al., 1999) , and were maintained in DME containing 10% FBS. Retrovirus-infected PS-2(À/À) MEFs were randomly coded with alphabetical letters to avoid bias during the analysis. Cells were trypsinized 2 days after the infection and cell numbers were determined using the Z2 Coulter cell counter. Cells were plated in multiple 12-well dishes at a plating density of 750 cells per well in 1 ml of media. Triplicates of each subline were counted 1 day (day 1) after the plating, and every 2 days thereafter (days 3, 5 and 7). Cell counts were normalized to the value obtained for day 1 and expressed as relative cell numbers at each time point. t-Tests were based on day 7 results, comparing cells expressing each of the PS-2 alleles to vector control. with statistical analyses, and P Ray for DNA specimens. This work was funded by the USAMRMC with fellowship to MDT, the Canadian Breast Cancer Research Initiative (ILA, JK), the National Cancer Institute of Canada with funds provided by the Terry Fox Run (ILA) and NCI/NIH (U01 CA69467 (ILA)).
